With the explosion of high-throughput data, an effective integrative analysis is needed to decipher the knowledge accumulated in multiple studies. However, batch effects, patient heterogeneity, and disease complexity all complicate the integration of data from different sources. Here we introduce TOMAS, a novel meta-analysis framework that transforms the challenging meta-analysis problem into a set of standard analysis problems that can be solved efficiently. This framework utilizes techniques based on both p-values and effect sizes to identify differentially expressed genes and their expression change on a genome-scale. The computed statistics allow for topology-aware pathway analysis of the given phenotypes, where topological information of genes is taken into consideration. We compare TOMAS with four metaanalysis approaches, as well as with three dedicated pathway analysis approaches that employ multiple datasets (MetaPath). The eight approaches have been tested on 609 samples from 9 Alzheimer's studies conducted in independent labs for different sets of patients and tissues. We demonstrate that the topology based meta-analysis framework overcomes noise and bias to identify pathways that are known to be implicated in Alzheimer's disease. While presented here in a genomic data analysis application, the proposed framework is sufficiently general to be applied in other research areas.
INTRODUCTION
Advanced techniques in sequencing and microarray assays have transformed biological research by enabling comprehensive monitoring of biological systems. Vast amounts of data of all types have accumulated in many public repositories, such as Gene Expression Omnibus (GEO) [1] , Array Express [2] , and The Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov). Gene expression data, as measured by microarray and high-throughput sequencing, are particularly abundant in public repositories, such that many diseases are represented by a dozen studies or more.
A typical comparative analysis of molecular data generally yields a set of genes that are differentially expressed (DE) between the conditions. These sets of DE genes contain the genes that are likely to be involved in the biological processes responsible for the disease. However, such sets of genes are usually insufficient to reveal the underlying biological mechanisms. Therefore, researchers have developed a variety of knowledge bases that map genes to functional modules. These knowledge bases, such as the Kyoto Encyclopedia of Genes and Genomes (KEGG) [3] or Reactome [4] , contain graphs that describe how genes interact together to accomplish specific biological processes. OverRepresentation Analysis (ORA) [5] , Gene Set Enrichment Analysis (GSEA) [6] , Gene Set Analysis (GSA) [7] , and Impact Analysis [8] , are examples of approaches designed to identify the pathways that are relevant in a given condition.
Remarkably, due to inherent bias present in individual studies, independent studies of the same disease often yield completely different lists of differential expressed (DE) genes, making interpretation extremely difficult [9, 10] . This problem is not resolved by simply analyzing the same individual datasets at the system level, as pathway analysis results are also often inconsistent as well [11] . Effective meta-analysis approaches, which are statistical methods for the quantitative analysis of independent but related studies, are needed to unify the biological knowledge spread over such similar studies with apparently incongruent results.
Meta-analysis of gene expression data has primarily been used for DE gene detection [12] . Early meta-analyses simply performed the intersection or union of DE gene lists obtained from individual studies [13, 14] , resulting in a single list which is either too conservative or too inclusive, respectively. Rhodes et al. [15] were among the earliest to apply Fisher's method [16] for DE gene detection. Since then, other pvalue based meta-analysis methods have been applied, such as Stouffer's method [17] , minP [18] , and maxP [19] .
Recently, meta-analysis has also been used to combine multiple experiments for on the pathway level [11, 20, 21, 14] . Kaever et al. [20] used Fisher's and Stouffer's method to combine p-values of pathways from independent studies. Nguyen et al. [11] added another level of meta-analysis to make better use of large number of samples within individual studies. Shen et al. [21] developed a dedicated approach, named MetaPath, that performs meta-analysis at both the gene and pathway level separately, and then combines the results to give the final p-value and ranking of pathways.
The major drawback of these p-value-based meta-analysis approaches is that they neglect the actual expression changes, i.e. effect sizes. This results in a critical information loss. While p-value is partly a function of effect size, it is also partly a function of sample size [22] . For example, with large sample size, a statistical test will almost always demonstrate a significant difference, unless the effect size is exactly zero. In reality, any individual study will include some degree of batch effects, sampling/study bias, noise, and measurement errors. Simply combining individual p-values would not be able to correct such problem. On the contrary, meta-analysis of effect sizes across all studies would definitely compensate for and eliminate such random effects [22, 23] .
Another limitation of p-value based meta-analyses is that they work under the assumption that the p-values provided by the individual statistical tests follow a uniform distribution under the null hypothesis. Previous reports describe non-uniform distributions of p-values under the null as due to specific factors such as improper normalization, crosshybridization, poorly characterized variance, heteroskedasticity in microarray data analysis [24, 25] .
Here we propose TOMAS (TOpology-aware Meta-Analysis applied to System biology), a new meta-analysis approach that utilizes techniques based on both p-values and effect sizes to combine independent studies. Our contribution is two-fold. First we use empirical distributions to calculate p-values for individual studies. This approach avoids making assumptions about null distributions of gene expression and thus compensates for potential bias. Second, the metaanalysis of effect sizes accurately estimates the central tendency of expression change for individual genes. The estimated genome-scale expression change allows for topologyaware analysis, in which gene interaction and signal propagation are taken into consideration.
We illustrate the new approach using 609 samples from 9 Alzheimer's studies conducted in independent labs for different sets of patients and tissues. We compare TOMAS with 7 other approaches: GSEA and GSA combined with Fisher's method [16] and addCLT [11] , plus 3 MetaPath approaches [21] . TOMAS outperforms existing approaches to identify pathways relevant to the disease. Our results suggest that the combination of both p-value based and effect based meta-analysis techniques provides more power and robustness than each taken alone. While presented here in the context of pathway analysis, the framework can be modified to adapt to other domains or applications, such as biomarker detection, genome-wide association studies (GWAS), or enrichment analysis (Gene Ontology, gene set analysis).
METHODS
The pipeline consists of three main modules: i) identifying genes that are differentially expressed under the disease condition, ii) estimate the expression change (effect size) of the genes, and iii) perform pathway analysis using the calculated statistics. The first and second modules essentially represent two different meta-analysis approaches at the gene level -one is based on p-value while another is based on effect-size. In Figure 1 , the purple arrows show the detailed steps of the first module while the blue arrows display the steps of the second module. The results obtained from the two modules then serve as the input for the topology-aware pathway analysis.
To identify differentially expressed genes, we first calculate p-values for each gene in each study, and then combine the p-values for each gene across independent studies. Study-specific and gene-specific empirical distributions of tstatistics are calculated by randomly assigning class labels to samples. Each distribution consists of 1, 000 random tstatistics. The left-and right-tailed p-values are calculated by comparing the actual t-statistic obtained from the real grouping against these empirical distributions. The p-values are then combined separately for the left and right tails. The final p-value for the gene is set to twice the minimum of the two combined p-values (see Section 2.1 for more details).
To estimate the central tendency of effect sizes, we first compute standardized mean difference (SMD) for each gene in each study. We next estimate the overall effect size using the random-effects model and the REstricted Maximum Likelihood (REML) algorithm [26] . This overall estimated effect size represents the change in expression of the gene under the effect of the disease (Section 2.2).
The combined p-values and the estimated effect sizes represent the evidence from which we will infer the differential expression between the two phenotypes. These statistics can be used as the input for analyses that are routinely done in pathway analysis (Section 2.3). The difference is that these statistics are gathered from multiple independent studies and thus are expected to accurately represent the real expression change of genes on a genome-scale. Technical details of each step are described in the following sections.
Computing cumulative p-values

Empirical hypothesis testing
In this framework, we use the t-statistic as the discriminating statistic between the conditions (disease vs. healthy). Formally, denoting x1 and x2 as the two groups of measurements to be compared, the two-sample t-statistic for unequal variances is defined as:
wherex1 andx2 are sample means, n1 and n2 are sample sizes, s .m]), we randomly divide the biological samples of the dataset into two groups and then calculate the t-statistic for each gene. We repeat this step 1, 000 times to construct the empirical distributions ξ 
This combined p-value of the gene represents how unlikely the cumulative differential expression is observed by chance.
In this work, we use the t-statistic is as the discriminating statistic between the two phenotypes. However, we acknowledge that the t-statistic can be substituted by any other statistics to suit the purpose of the analysis.
Combining p-values
Existing methods of combining independent p-values include Fisher's method [16] , Stouffer's method [17] , minP [18] , maxP [19] , and addCLT [27, 11, 28 ]. Fisher's method uses the negative log product of the p-values as the summary statistic. Under the null hypothesis, this statistic follows a chi-square distribution with 2m degrees of freedom. Similarly, the test statistic of Stouffer's method is the sum of pvalues transformed into standard normal variables, divided by the square root of m. This summary statistic follows a standard normal distribution if the null hypothesis is true. A major drawback of Fisher's and Stouffer's method is that they are sensitive to outliers. For example, if one of the individual p-value approaches zero, the combined p-value will be zero regardless of other individual p-values. The same is true for the minP's and maxP's statistic, where outliers can greatly influence the combined p-value.
On the contrary, the addCLT method uses the average of p-values as the test statistic and therefore it is more robust against extreme p-values. Denoting the individual p-values to be combined as P1, P2, . . . , Pm, the summary statistic is defined as
. The probability density function (pdf) is derived from a linear transformation of the Irwin-Hall distribution [29, 30] as follows:
When m is large, the computation of Equation (3) can lead to underflow/overflow problems. Therefore, we use the Central Limit Theorem [31] to estimate this distribution in this case. The variable X is the mean of m independent and identically distributed (i.i.d.) random variables that follow a uniform distribution with a mean of 1 2 and a variance of 1 12 . From the Central Limit Theorem [31] , the average of such m i.i.d. variables follows a normal distribution with mean µ = 
Estimating overall effect sizes
Standardized mean difference
Since gene expression is scaled differently in each study, it is more reasonable to use the standardized mean difference (SMD) to measure expression changes, instead of the raw mean difference. Here we briefly describe two popular SMD metrics: Cohen's d [32] and Hedge's g [33] .
Consider a study composed of two independent groups. Letx1 andx2 represent the sample means for that gene in the two groups, n1 and n2 the number of samples in each group. The pooled standard deviation of the two groups and Cohen's d are calculated as follows:
We note that Cohen's d, which is based on sample averages, tends to overestimate the population effect size for small samples. Let n be the degrees of freedom used to estimate S pooled , i.e. n = n1 + n2 − 2. The corrected effect size, or Hedges' g [33] , can be computed as follows:
where Γ is the gamma function. In this work, we use Hedge' g as the standardized mean difference (SMD) between disease and control groups for each gene.
Restricted maximum likelihood estimation
Consider a collection of m studies where the effect size estimates, y1, . . . , ym have been derived as shown in Equation (7) . A fixed-effects model would assume that there is one true effect size which underlies all of the studies in the analysis, such that all differences in observed effects are due to sampling error. However, this assumption is implausible since it cannot account for heterogeneity between studies [34, 35, 36] (see Appendix A for details).
In contrast, the random-effects model allows for variability of the true effect. For example, the effect size might be higher (or lower) in studies where the participants are older, or have a healthier lifestyle compared to others. The random-effects model assumes that each effect size estimate can be decomposed into two variance components by a two stage hierarchical process [35, 37, 38] . The first variance represents the variability of the effect size across studies, and the second variance represents the sampling error within each study. We can write the random-effects model as:
where µ is the central tendency of the effect size, N (0, σ 2 ) represents the error term by which the effect size in the i th study differs from the central tendency µ, and N (0, σ The derivation and formulation of the REstricted Maximum Likelihood (REML) algorithm has been described in the literature [35, 39, 40] (see Appendix B for details). The REML estimator ofμ and the combined p-value of individual genes serve as the input of Impact Analysis (Section 2.3).
Topology-aware pathway analysis
Impact Analysis [41, 8] combines two types of evidence: (i) the over-representation of DE genes in a given pathway, and (ii) the perturbation of that pathway, caused by disease, as measured by propagating expression changes through the pathway topology. These two aspects are captured by the probability values, PNDE and PP ERT , respectively.
The first p-value, PNDE, is obtained using the hypergeometric model, which is the probability of obtaining at least the observed number of differentially expressed genes. The input of the hypergeometric test consists of: i) the set of all measured genes, and ii) the set of DE genes. The former is the set of genes that are common in all datasets while the latter is the set of genes that have a combined p ≤ 0.01.
The second p-value, PP ERT , depends on the identity of the specific genes that are differentially expressed as well as on the known interactions between the genes. It is calculated based on the perturbation factor in each pathway. The perturbation factor of a gene, P F (g), is defined as:
The
The total accumulated perturbation in the pathway is then computed as:
The null distribution of Acc(Pi) is built by permuting both sample and gene labels of expression changes. The p-value, PP ERT , is then calculated by the probability of having values more extreme than the actually observed Acc(Pi).
To compute PP ERT , the following input is required: the graphical representation of the pathway, the set of DE genes, and their estimated effect sizes. The graphical representation of pathways is obtained from KEGG; the list of DE genes is obtained from the combined p-values (Section 2.1.2); the estimated effect sizes are obtained from the randomeffects model and the REML algorithm (Section 2.2.2).
The two p-values, PNDE and PP ERT , are then combined using Fisher's method to get a p-value that represents how likely the pathway is impacted under the effect of the disease.
RESULTS
We compare the performance of TOMAS with 7 existing approaches: GSEA and GSA, each combined with Fisher's method and addCLT, plus 3 MetaPath approaches: gene level, pathway level and combined. We analyze 9 Alzheimer's gene expression datasets that were generated in independent labs for different sets of patients and tissues. The 9 datasets are GSE1297 (hippocampus), GSE4757 (entorhinal cortex), GSE5281 (entorhinal cortex, medial temporal gyrus, posterior cingulate, superior frontal gyrus, hippocampus, and primary visual cortex), GSE16759 (parietal lobe), GSE18309 (peripheral blood mononuclear cell), GSE28146 (hippocampus), GSE36980 (frontal cortex, temporal cortex, and hippocampus), GSE39420 (brain tissues), and GSE48350 (entorhinal cortex, post-central gyrus, hippocampus, and superior frontal gyrus). Table 1 shows the details of each dataset, such as the number of control and disease samples, tissues, and platforms. Pre-processing was performed on individual datasets using the threestep function from the package affyPLM version 1.38.0 [42] . The parameters used for the threestep function are: robust multi-array analysis (RMA) background adjustment, quantile normalization, and median polish summarization. We use the KEGG database version 76, which includes 182 signaling pathways.
There is a dedicated pathway in KEGG, Alzheimer's disease, that was created precisely in order to describe the known mechanisms involved in this disease. However, it is well known that Alzheimer's disease, Parkinson's disease, and Huntington's disease share many signaling mechanisms and affect the same tissue (brain). The common elements include abnormal protein folding, endoplasmic reticulum stress, and ubiquitin mediated breakdown of proteins, leading to programmed cell death [43, 44, 45, 46] . In addition, previous studies [47] have shown the presence of a strong crosstalk that makes these three neurological diseases pathways appear as significant simultaneously, due to their dominant mitochondrial module. Therefore, we expect a good analysis method to find all three of these pathways as significant in this meta-analysis of Alzheimer's data.
For each of the nine datasets, GSEA produces a list of 182 p-values for 182 signaling pathways. In other words, nine pvalues will be calculated for each pathway -one per study. These p-values are independent and thus can be combined using either Fisher's method or addCLT. Therefore, each meta-analysis method produces a list of pathways ranked according to the combined p-values. Similarly, we also combine GSA p-values using Fisher's and the addCLT method. The p-values of each list are then adjusted for multiple comparison using False Discovery Rate (FDR). Table 2 There are 23 significant pathways using GSA with Fisher's method, many of which are likely to be false positives. Each of the top 17 pathways has a combined p-value equal to zero because the p-value was zero for at least one of the datasets. The pathways Alzheimer's disease, Huntington's disease, and Parkinson's disease are not reported as significant and are ranked at the positions 26 th , 25 th , and 33 rd , respectively. GSA with addCLT produces a single false positive, the Retrograde endocannabinoid signaling, but it is also unable to identify any of the true positive pathways. The three neurological disorder pathways are also ranked at higher positions (4 th , 6 th , and 15 th ). Similarly, GSEA combined with Fisher's method and add-CLT also fail to identify any of the three neurological disorder pathways as significant. GSEA with Fisher's method rank the pathways Alzheimer's disease, Huntington's disease, and Parkinson's disease at positions 8 th , 10 th , and 17 th , respectively; GSEA with the addCLT rank them at positions 49 th , 10 th , and 47 th , respectively. In summary, all four approaches fail to provide the needed power to identify the three neurological disorder pathways as significant at the significance threshold of 1%. We also employ MetaPath to combine the 9 Alzheimer's studies. MetaPath performs meta-analysis at both gene and pathway levels separately, and then combines the results to give the final p-value and ranking of pathways. At the gene level, MetaPath calculates a t-statistic for each gene in each study, then combines them using the maxP method [19] . A pathway enrichment score is calculated using these genes, for each pathway, using a Kolmogorov-Smirnov test, and assessed for significance with a sample-wise permutation test. At the pathway level, MetaPath calculates pathway enrichment for each individual study, then combines the p-values, again using the maxP method [19] . Finally, p-values from the gene and pathway level are integrated using minP [18] to give the final p-value and ranking of pathways. Table 3 shows the top 10 ranked pathways and adjusted p-values of the three MetaPath approaches: MetaPath G (gene-level), MetaPath P (pathway-level), and MetaPath I (both levels). MetaPath G identifies no significant pathway. The three pathways Alzheimer's disease, Huntington's disease, and Parkinson's disease are ranked at positions 72 nd , 18 th , and 42 nd , respectively. Similarly, MetaPath P produces no significant pathway and ranks the three pathways at positions 90 th , 43 rd , and 161 st , respectively. In consequences, the combination of these two methods, MetaPath I, also fails to identify the three neurological disorder pathways as significant (adjusted p-values 0.87, 0.97, and 0.91 with rankings 28 th , 89 th , and 63 rd , respectively). Finally, we apply TOMAS to combine the 9 studies. Statistical tests were one-sided and performed independently for the two null hypothesis that no genes are over-expressed and no genes are under-expressed. The one-sided p-values are calculated and then combined using the addCLT method [11] . The final p-value for a gene is set to twice the minimum of the two one-sided p-values. The p-values for the whole set of genes are then adjusted for multiple comparisons using FDR. We use the standard 1% as the significance cutoff to identify the DE genes. For effect sizes, we first calculate Hedge's g [33] in each study, and then estimate the overall effect size for each gene using the REML algorithm [26] . The DE genes and their expression change (effect size) then serve as input for Impact Analysis [8] .
The results of TOMAS are shown in Table 3 . TOMAS identifies 7 pathways as significant using the 1% threshold. All three neurological disorder pathways are significant and are ranked at the very top. The target pathway Alzheimer's disease is the most significant with adjusted p = 10 −6 . There are totally 3, 971 KEGG genes that are measured in the 9 datasets. The framework identified 898 genes (23%) that are differentially expressed using the cutoff FDR=1%. The pathway Alzheimer's disease has 62 DE genes (out of 142); Parkinson's disease has 59 DE genes (out of 111); Huntington's disease has 77 DE genes (out of 155). Most of these DE genes belong to the mitochondrial module that is included in all the three neurological disease pathways.
Given that the pathway Alzheimer's disease is influenced by the mitochondrial compartment, which is strongly implicated in the disease [43, 44, 45, 46] , it is not surprising that other pathways with strong mitochondrial components also garner high rankings. Previous studies [47] have shown the presence of a cross-talk that makes the neurological disease pathways, Alzheimer's disease, Parkinson's disease and Huntington's disease, along with Cardiac muscle contraction and Non-alcoholic fatty liver disease (NAFLD), appear as significant simultaneously, due to their dominant mitochondrial module. Cardiac muscle contraction has a strong mitochondrial component and is highly dependent on calcium signaling, which is also prevalent in Synaptic vesicle cycle, Alzheimer's disease, and Huntington's disease. Ca2+ regulates mitochondrial metabolism, but calcium overload to mitochondria can result in cell damage from reactive oxygen [48] .
CONCLUSIONS
In this article, we present a novel topology-aware metaanalysis able to combine multiple studies and identify the signaling pathways that are significantly impacted in a given phenotype. This approach first calculates the empirical pvalues for each gene in each study and then combines them using an approach based on the Central Limit Theorem. The combined p-value of a gene represents how unlikely the differential expression of the gene is observed by chance. At the same time, the framework also estimates the overall effect sizes using the REstricted Maximum Likelihood (REML) algorithm. The two statistics then serve as input for Impact Analysis which identifies the pathways that are impacted by the given disease.
To evaluate this framework, we examined 609 samples from 9 Alzheimer's gene expression datasets. TOMAS was compared against 7 different approaches, GSA and GSEA combined with Fisher's method and addCLT, plus three approaches implemented in the MetaPath package. We demonstrated that TOMAS outperforms existing approaches to correctly identify pathways relevant to the disease.
The main innovation of TOMAS is that it addresses the challenging meta-analysis problem by transforming it into a set of standard analysis problems that can be solved efficiently.
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